Adding COVID to Cancer: Does Cancer Status Influence COVID-19 Infection Preventive Behaviors?
pdf

Keywords

COVID 19
Preventive Behaviors
cancer survivors
health belief model

Abstract

Introduction
A better understanding of how to promote disease mitigation and prevention behaviors among vulnerable populations, such as cancer survivors, is needed. This study aimed to determine patterns of and factors associated with COVID-19-related preventive behaviors among cancer survivors and assess whether the COVID-19 preventive behaviors of cancer survivors differ from the general population.
Methods
In June 2020, an online survey of adults (N=897) assessed predictors of COVID-19-related preventive behaviors, including socio-demographics, COVID-19 beliefs and perceptions (Health Belief Model [HBM] variables), and cancer statuses (cancer survivors currently in treatment, cancer survivors not currently in treatment, and individuals with no history of cancer). An average score of respondent engagement in eight preventive behaviors was calculated. Differences in HBM variables and preventive behaviors by cancer status were assessed using ANCOVAs. Hierarchical multiple regression analyzed associations among socio-demographics, HBM constructs, cancer statuses, and engagement in COVID-19 preventive behaviors.
Results
Participants reported engaging in 3.5 (SD=0.6) preventive behaviors. Cancer survivors not in treatment engaged in preventive behaviors significantly less than the comparison group. In the final adjusted model, after adding COVID-19 beliefs and perceptions, cancer status was no longer significant. All HBM constructs except perceived susceptibility were significant predictors of preventive behaviors.
Conclusions
COVID-19 beliefs and perceptions were more robust predictors preventive behaviors than cancer status. Nonetheless, public health organizations and practitioners should communicate the risk and severity of infection among cancer survivors and emphasize the need to engage in protective behaviors for COVID-19 and other infectious diseases with this vulnerable population.

https://doi.org/10.15167/2421-4248/jpmh2024.65.1.2888
pdf

References

Centers for Disease Control and Prevention. (2021). Symptoms of COVID-19. National Center for Immunization and Respiratory Diseases (NCIRD), Division of Viral Diseases. https://www.cdc.gov/coronavirus/2019-ncov/symptoms-testing/symptoms.html

Acosta, M. A. T., & Singer, B. D. (2020). Pathogenesis of COVID-19-induced ARDS: implications for an ageing population. European Respiratory Journal, 56(3).

D’Antiga, L. (2020). Coronaviruses and immunosuppressed patients: the facts during the third epidemic. Liver Transplantation, 26(6), 832-834.

Fung, M., & Babik, J. M. (2021). COVID-19 in immunocompromised hosts: what we know so far. Clinical Infectious Diseases, 72(2), 340-350.

Liang, W., Guan, W., Chen, R., Wang, W., Li, J., Xu, K., . . . Liang, H. (2020). Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. The lancet oncology, 21(3), 335-337.

Jammu, A. S., Chasen, M. R., Lofters, A. K., & Bhargava, R. (2021). Systematic rapid living review of the impact of the COVID-19 pandemic on cancer survivors: update to August 27, 2020. Supportive Care in Cancer, 29(6), 2841-2850.

Nekhlyudov, L., Duijts, S., Hudson, S. V., Jones, J. M., Keogh, J., Love, B., . . . Yu, X. (2020). Addressing the needs of cancer survivors during the COVID-19 pandemic. In: Springer.

Al-Quteimat, O. M., & Amer, A. M. (2020). The impact of the COVID-19 pandemic on cancer patients. American Journal of Clinical Oncology.

Sun, L., Surya, S., Le, A. N., Desai, H., Doucette, A., Gabriel, P., ... & Maxwell, K. N. (2021). Rates of COVID-19–related outcomes in cancer compared with noncancer patients. JNCI cancer spectrum, 5(1), pkaa120.

Centers for Disease Control and Prevention. When You've Been Fully Vaccinated (2021). https://www.cdc.gov/coronavirus/2019-ncov/vaccines/fully-vaccinated.html

Shankar, A., Saini, D., Roy, S., Jarrahi, A. M., Chakraborty, A., Bharati, S. J., & Taghizadeh-Hesary, F. (2020). Cancer care delivery challenges amidst coronavirus disease–19 (COVID-19) outbreak: specific precautions for cancer patients and cancer care providers to prevent spread. Asian Pacific journal of cancer prevention: APJCP, 21(3), 569.

Islam, J. Y., Camacho-Rivera, M., & Vidot, D. C. (2020). Examining COVID-19 preventive behaviors among cancer survivors in the United States: an analysis of the COVID-19 impact survey. Cancer Epidemiology and Prevention Biomarkers, 29(12), 2583-2590.

Islam, J. Y., Vidot, D. C., Havanur, A., & Camacho-Rivera, M. (2021). Preventive Behaviors and Mental Health-related symptoms among immunocompromised adults during the COVID-19 pandemic: an analysis of the COVID Impact Survey. AIDS Research and Human Retroviruses, 37(4), 304-313.

Guidry, J. P., Miller, C. A., Ksinan, A. J., Rohan, J. M., Winter, M. A., Carlyle, K. E., & Fuemmeler, B. F. (2021). COVID-19–Related Misinformation among Parents of Patients with Pediatric Cancer. Emerging Infectious Diseases, 27(2), 650.

Burke, P. F., Masters, D., & Massey, G. (2021). Enablers and barriers to COVID-19 vaccine uptake: An international study of perceptions and intentions. Vaccine, 39(36), 5116-5128.

Lee, J. J., Kang, K. A., Wang, M. P., Zhao, S. Z., Wong, J. Y. H., O'Connor, S., ... & Shin, S. (2020). Associations between COVID-19 misinformation exposure and belief with COVID-19 knowledge and preventive behaviors: cross-sectional online study. Journal of medical Internet research, 22(11), e22205.

Myers, L., & Goodwin, R. (2012). Using a theoretical framework to determine adults' intention to vaccinate against pandemic swine flu in priority groups in the UK. Public Health, 126, S53-S56.

Rosenstock, I. M. (1974a). The health belief model and preventive health behavior. Health education monographs, 2(4), 354-386.

Rosenstock, I. M. (1974b). Historical origins of the health belief model. Health education monographs, 2(4), 328-335.

Coe, A. B., Gatewood, S. B., & Moczygemba, L. R. (2012). The use of the health belief model to assess predictors of intent to receive the novel (2009) H1N1 influenza vaccine. Innovations in pharmacy, 3(2), 1.